Evaluation of the Safety and Pharmacokinetics of CVN293 in Healthy Volunteers for Neurodegenerative Disorders

The primary objective of this study is to evaluate the **safety** of the investigational drug CVN293 in healthy volunteers. This is clinically relevant as it provides essential safety data that is crucial for determining the potential of CVN293 as a therapeutic option for **neurodegenerative disorders**. Understanding the safety profile in a healthy population is a foundational step before considering further clinical trials in patients with the target condition.

The clinical trial focuses on **neurodegenerative disorders** and includes a study population comprising both male and female participants. The age range of the participants is categorized as adults, although specific age limits are not provided. The trial involves a vulnerable population, indicating that special considerations are taken into account for the participants' safety and well-being. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection process for the trial population and any key inclusion or exclusion criteria have not been disclosed. The absence of detailed participant data suggests that the sponsor has chosen not to release this information.

The clinical trial is designed to evaluate the **safety** and pharmacokinetics of the investigational drug CVN293 in healthy volunteers. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing the safety profile of the drug. The trial employs a **randomized**, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is approximately one year, with recruitment starting on July 31, 2023, and the trial expected to conclude by July 31, 2024.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment to ensure that participants meet the necessary health standards for inclusion in the trial. Following successful screening, participants will be randomly assigned to receive either the investigational drug or a placebo, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study.

Throughout the trial, participants will attend regular follow-up visits to monitor their health and collect data on the drug's pharmacokinetics and safety. These visits will include physical examinations, laboratory tests, and assessments of any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather comprehensive data on the drug's effects.

The expected length of participant involvement is contingent upon the trial's schedule and individual response to the investigational drug. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical reasons deemed necessary by the investigators. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of July 31, 2023, and an estimated end date of July 31, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a systematic approach to collect and analyze data, ensuring that the results are scientifically valid and reliable. The trial's duration and phase indicate an early-stage investigation, focusing on initial efficacy and safety assessments. The absence of detailed endpoints suggests that the trial may be exploratory in nature, aiming to gather preliminary data to inform future studies.